Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | NAMPT | P43490 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307464 | 0.93 | ROCK2 (0.76) | ROCK2CYP3A4CYP2C19NAMPTSMN1; SMN2 | |
| SCHEMBL306324 | 0.90 | ROCK2 (0.78) | ROCK2CYP3A4CYP2C19SMN1; SMN2NPC1 | |
| SCHEMBL307242 | 0.88 | ROCK2 (0.82) | ROCK2CYP3A4CYP2C19NAMPTSMN1; SMN2 | |
| SCHEMBL15888411 | 0.88 | NAMPT (0.68) | ROCK2NAMPTSMN1; SMN2RXFP1NPC1 | |
| SCHEMBL306728 | 0.87 | ROCK2 (0.66) | ROCK2CYP3A4CYP2C19NAMPTSMN1; SMN2 | |
| SCHEMBL10159840 | 0.86 | ROCK2 (1.00) | ROCK2CYP3A4CYP2C19NAMPT | |
| SCHEMBL321410 | 0.86 | ROCK2 (0.81) | ROCK2CYP3A4CYP2C19NAMPT | |
| SCHEMBL307583 | 0.85 | ROCK2 (0.80) | ROCK2CYP3A4CYP2C19NAMPTSMN1; SMN2 | |
| SCHEMBL307681 | 0.85 | ROCK2 (0.76) | ROCK2CYP3A4CYP2C19SMN1; SMN2NPC1 | |
| SCHEMBL306624 | 0.85 | ROCK2 (0.79) | ROCK2CYP3A4CYP2C19NAMPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114869-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | claimed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | claimed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | claimed |
| EP-2114869-A1 | RHO KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | claimed |
| WO-2008086047-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-17 | — | — | WO | claimed |
| EP-2114869-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| WO-2008086047-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041645-A1 | RHO KINASE INHIBITORS | CIT, ROCK1, RHOT2 | ROCK2 4/4885CYP3A4 2048/4885CYP2C19 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.